These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30124737)

  • 1. What Lies Beneath the Face Value of a BOX WARNING: A Deeper Look at Brodalumab.
    Hashim PW; Chen T; Lebwohl MG; Marangell LB; Kircik LH
    J Drugs Dermatol; 2018 Aug; 17(8):s29-s34. PubMed ID: 30124737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Closer Look at the Data Regarding Suicidal Ideation and Behavior in Psoriasis Patients: The Case of Brodalumab.
    Rodriguez-Bolanos F; Gooderham M; Papp K
    Skin Therapy Lett; 2019 Jul; 24(4):1-4. PubMed ID: 31339678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study.
    Lebwohl MG; Blauvelt A; Menter A; Papp KA; Guenthner S; Pillai R; Israel RJ; Jacobson A
    Am J Clin Dermatol; 2019 Dec; 20(6):863-871. PubMed ID: 31493163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depression and suicidality in psoriasis and clinical studies of brodalumab: a narrative review.
    Koo J; Ho RS; Thibodeaux Q
    Cutis; 2019 Dec; 104(6):361-365. PubMed ID: 31939925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brodalumab: A Review of Safety.
    Rusta-Sallehy S; Gooderham M; Papp K
    Skin Therapy Lett; 2018 Mar; 23(2):1-3. PubMed ID: 29562088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-17 inhibitors for psoriasis.
    Paek SY; Frieder J; Kivelevitch D; Menter MA
    Semin Cutan Med Surg; 2018 Sep; 37(3):148-157. PubMed ID: 30215631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
    AbuHilal M; Walsh S; Shear N
    J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis.
    Galluzzo M; Talamonti M; D'adamio S; Bianchi L
    Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):679-691. PubMed ID: 28460549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.
    Papp KA; Reich K; Paul C; Blauvelt A; Baran W; Bolduc C; Toth D; Langley RG; Cather J; Gottlieb AB; Thaçi D; Krueger JG; Russell CB; Milmont CE; Li J; Klekotka PA; Kricorian G; Nirula A
    Br J Dermatol; 2016 Aug; 175(2):273-86. PubMed ID: 26914406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brodalumab-associated generalized eczematous eruption in a difficult-to-treat psoriasis patient: management without brodalumab withdrawal.
    Danset M; Hacard F; Jaulent C; Nosbaum A; Berard F; Nicolas JF; Goujon C
    Eur J Dermatol; 2020 Dec; 30(6):741-743. PubMed ID: 33337328
    [No Abstract]   [Full Text] [Related]  

  • 11. The safety of brodalumab for the treatment of psoriasis.
    Iznardo H; Puig L
    Expert Opin Drug Saf; 2020 Apr; 19(4):365-372. PubMed ID: 32053396
    [No Abstract]   [Full Text] [Related]  

  • 12. Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy.
    Roman M; Chiu MW
    Drug Des Devel Ther; 2017; 11():2065-2075. PubMed ID: 28744098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of IL-17 inhibitors for psoriasis.
    Amin M; Darji K; No DJ; Bhutani T; Wu JJ
    J Dermatolog Treat; 2018 Jun; 29(4):347-352. PubMed ID: 29058501
    [No Abstract]   [Full Text] [Related]  

  • 14. New plaque psoriasis approval carries suicide warning.
    Mullard A
    Nat Rev Drug Discov; 2017 Mar; 16(3):155. PubMed ID: 28248935
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials.
    McMichael A; Desai SR; Qureshi A; Rastogi S; Alexis AF
    Am J Clin Dermatol; 2019 Apr; 20(2):267-276. PubMed ID: 30471012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents.
    Chiricozzi A; Romanelli M; Saraceno R; Torres T
    Expert Opin Drug Saf; 2016 Dec; 15(12):1653-1659. PubMed ID: 27554637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials.
    Lebwohl MG; Papp KA; Marangell LB; Koo J; Blauvelt A; Gooderham M; Wu JJ; Rastogi S; Harris S; Pillai R; Israel RJ
    J Am Acad Dermatol; 2018 Jan; 78(1):81-89.e5. PubMed ID: 28985956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brodalumab: the first anti-IL-17 receptor agent for psoriasis.
    Puig L
    Drugs Today (Barc); 2017 May; 53(5):283-297. PubMed ID: 28650001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment.
    Papp K; Leonardi C; Menter A; Thompson EH; Milmont CE; Kricorian G; Nirula A; Klekotka P
    J Am Acad Dermatol; 2014 Dec; 71(6):1183-1190.e3. PubMed ID: 25313095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guselkumab for the treatment of moderate-to-severe plaque psoriasis.
    Yang EJ; Sanchez IM; Beck K; Sekhon S; Wu JJ; Bhutani T
    Expert Rev Clin Pharmacol; 2018 Apr; 11(4):333-344. PubMed ID: 29478344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.